GlaxoSmithKline on Monday said it does not expect to receive FDA approval for its human papillomavirus vaccine Cervarix until late 2009, Reuters reports. GSK said it has decided to wait until results from a Phase III trial of the vaccine are available before seeking U.S. approval.
Share and Enjoy:
These icons link to social bookmarking sites where […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
VGX Pharmaceuticals, Inc. (VGX) announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application for its DNA vaccine for cervical cancer therapy, VGX-3100. The Company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008. […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
The Centers for Medicare & Medicaid Services (CMS) announced additional updates to the information it uses in determining which drugs may be covered under Medicare Part B when used to treat patients undergoing cancer treatment through chemotherapy. CMS will add Elsevier Gold Standard’s Clinical Pharmacology compendium to the list of […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
Insightful updates on onco-urological issues were the focus of the 3rd ESU masterclass, which started in Barcelona on Friday 27 June. There were 150 participants who listened to a faculty of 12 internationally renowned experts in urological cancers. The European Board of Urology (EBU) organised a written examination following the masterclass […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, a research team led by investigators from The University of Texas M. D. Anderson Cancer Center reports in the July 3rd edition of The New England […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
A study by an international team of researchers found that an experimental drug that stops blood vessels that feed tumors from forming was able, in a small number of patients, to slow down the progression of advanced thyroid cancer that has spread to other sites.
Share and Enjoy:
These icons link to social […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
More than 170 physicians and health care professionals specializing in the treatment of liver metastases gathered May 2-3 in Chicago for the fourth annual clinical symposium on liver-directed microsphere therapy. The symposium, sponsored by the Goshen Center for Cancer Care, was supported by an educational grant provided by Sirtex Medical. Sirtex manufactures SIR-Spheres microspheres, the […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
Virginia Commonwealth University and VCU Massey Cancer Center researchers have uncovered how a gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), induces a bystander effect that kills cancer cells not directly receiving mda-7/IL-24 without harming healthy ones, a discovery that could lead to new therapeutic strategies to fight metastatic disease.
Share and Enjoy:
These icons link to social bookmarking […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
Rising public awareness about breast cancer and the treatments available has greatly improved revenues in the overall breast cancer therapeutics market. To thrive in this highly competitive market, drug developers must offer drugs that improve survival rates and the quality of life. New analysis from Frost & Sullivan, U.S.
Share and Enjoy:
These icons […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
Oncolin Therapeutics, Inc., (OTCBB:OCOL) announces that a team of scientists supported by an Oncolin Sponsored Research Agreement (SRA) and lead by Professor Waldemar Priebe from The University of Texas M. D. Anderson Cancer Center (UTMDACC) has discovered a new inhibitor of glycolysis, which is superior to the other known inhibitors. These results were confirmed both […]
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...